a Criteria considered for the choice pro/con local therapy +/− MDT. b Endpoints relevant for therapy decision in patients with oligo-metastatic PCa. MDT, metastasis-directed therapy; PROMs, patient-reported outcome measurements; PSA, prostate-specific antigen; PSADT, PSA doubling time.